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Abstract
Background: Synaptic Vesicle Protein 2 (SV2) and SV2-related protein (SVOP) are transporter-like proteins that localize to
neurotransmitter-containing vesicles. Both proteins share structural similarity with the major facilitator (MF) family of small
molecule transporters. We recently reported that SV2 binds nucleotides, a feature that has also been reported for another
MF family member, the human glucose transporter 1 (Glut1). In the case of Glut1, nucleotide binding affects transport
activity. In this study, we determined if SVOP also binds nucleotides and assessed its nucleotide binding properties.
Methodology/Principal Findings: We performed in vitro photoaffinity labeling experiments with the photoreactive ATP
analogue, 8-azido-ATP[c] biotin and purified recombinant SVOP-FLAG fusion protein. We found that SVOP is a nucleotide-
binding protein, although both its substrate specificity and binding site differ from that of SV2. Within the nucleotides
tested, ATP, GTP and NAD show same level of inhibition on SVOP-FLAG labeling. Dose dependent studies indicated that
SVOP demonstrates the highest affinity for NAD, in contrast to SV2, which binds both NAD and ATP with equal affinity.
Mapping of the binding site revealed a single region spanning transmembrane domains 9–12, which contrasts to the two
binding sites in the large cytoplasmic domains in SV2A.
Conclusions/Significance: SVOP is the third MF family member to be found to bind nucleotides. Given that the binding
sites are unique in SVOP, SV2 and Glut1, this feature appears to have arisen separately.
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Introduction
Regulated secretion in neurons and endocrine cells is mediated
by a specialized version of SNARE-mediated membrane fusion
(reviewed in [1]). The unique features of regulated secretion are
created, in part, by a cadre of proteins specific to neurons and
endocrine cells. Among these are SV2 [2–6] and SVOP [7], both
of which share structural similarity with the major facilitator (MF)
family of small molecule transporters [7,8].
SV2 is an essential protein that is required for normal
neurotransmission [9,10]. In neurons and endocrine cells lacking
SV2, the number of vesicles capable of fusing with the plasma
membrane, referred to as the readily releasable pool, is reduced
[11,12]. SV2 therefore appears to function as a modulator of
vesicle priming. There are three SV2 genes in mammal that
encode isoforms SV2A, SV2B and SV2C [13,14]. All three
isoforms demonstrate calcium-regulated binding to the calcium
sensor synaptotagmin [15–17], suggesting that SV2 influences
calcium-regulated priming through synaptotagmin. The recent
finding that SV2 binds adenine nucleotides suggests that its action
may regulate or be regulated by synaptic energy levels [18]. SV2A
is the binding site of the drug levetiracetam [19,20] and related
compounds [21], which are used in the treatment of epilepsy [22]
and show promise in the treatment of neuropathic pain [23,24]
and dyskinesias [25,26]. Thus the SV2 proteins constitute a
therapeutic target and are, at present, the only known drug target
in synaptic vesicles.
SVOP is distantly related to SV2, sharing 20–22% sequence
identity with SV2 [7]. SVOP is one of the first proteins expressed
in the developing nervous system [7,27], though beyond that very
little is known about the function of SVOP, or the related protein
SVOPL [28]. Although SVOP is structurally similar to SV2, it is
not clear that it performs a similar function. Like SV2, SVOP co-
purifies with synaptic vesicles, consistent with it being a synaptic
vesicle protein. However, immunolabeling studies of brain
revealed that it is also present in neuronal cell bodies [7], which
is not true of SV2.
We recently reported that SV2 binds nucleotides. To determine
if SVOP shares this feature of SV2, we assayed its nucleotide
binding properties. Our findings indicate that SVOP is a
nucleotide binding protein, but that both the specificity and
binding site differ from that of SV2.
Results
SVOP binds 8-azido-ATP
In a previous study [18], we found that SV2 is a nucleotide
binding protein. We showed that both purified recombinant SV2-
FLAG protein and native SV2 in the synaptic vesicle preparations
can be labeled with the photoreactive ATP analogue, 8-azido-
ATP[c] biotin. To test whether SVOP is a nucleotide binding
protein, we performed similar photoaffinity labeling experiments.
Affinity-purified, recombinant SVOP-FLAG fusion protein was
incubated with 8-azido-ATP[c] biotin in the presence or absence
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azido-ATP was incorporated into recombinant SVOP-FLAG
proteins. However, incorporation of the photoaffinity ATP
analogue did not occur without the UV-irradiation. Furthermore,
excess non-photoreactive ATP decreased the labeling. Our
attempt to measure labeling of endogenous SVOP in synaptic
vesicle preparation was hampered by the low abundance of SVOP
in synaptic vesicles and the lack of an efficient antibody for
immunoprecipitation. Given the results of SV2, however, it is
likely that the photoaffinity labeling in vitro reflects an ability of
SVOP to bind ATP in situ.
To determine the affinity of SVOP binding ATP, we measured
the binding of increasing amount of 8-azido-ATP (20–300 mM).
As shown in Figure 2, quantitative analysis of SVOP labeling
showed saturation with an apparent Kd value of 83 mM, a value
within physiological concentrations of ATP in cells, and similar to
the apparent Kd values measured for SV2 (,90 mM).
ATP, NAD, and GTP produce strong inhibition in SVOP
labeling
To determine the specificity of nucleotide binding by SVOP, we
tested the ability of 10-fold excess various nucleotides to compete
with 8-azido-ATP labeling. ATP, GTP, TTP, CTP, and NAD all
decreased labeling, though ATP, GTP and NAD displayed the
strongest inhibition. TTP and CTP produced the least inhibition
(Figure 3).
To compare the affinity of SVOP for ATP and NAD, we
analyzed the effects of increasing concentrations of these two
nucleotides on 8-azido-ATP labeling. As shown in Figure 4, ATP
competed with 8-azido-ATP binding to purified SVOP-FLAG
with half maximum inhibition concentration of ,0.75 mM. The
concentration of NAD that produced half maximum inhibition
was ,0.25 mM. Thus SVOP appears to have the highest affinity
for NAD, a feature that distinguishes it from SV2, which
demonstrates equal affinity for both adenine nucleotides.
Nucleotide binding maps to a region spanning
membrane domains 9 to 12 of SVOP
To identify the nucleotide-binding site(s) in SVOP, we first
applied chemical cleavage and enzymatic digestion to 8-azido-
ATP-labeled SVOP-FLAG. Hydroxylamine cleaves the bond
between Asn and Gly, with much less efficient cleavage at Asn-
Leu, Asn-Ala, and Asn-Met bonds [29]. SVOP contains an Asn-
Gly bond at residue 285–286 that is located in the cytoplasmic
Figure 1. Purified SVOP-FLAG fusion proteins are labeled with
8-azido-ATP-biotin. Recombinant SVOP-FLAG fusion protein was
purified from transfected HEK293 cells with Anti-FLAG M2 affinity gel.
About 5 mg protein preparation was used in each photoaffinity labeling
reaction with 100 mM 8-azido-ATP-biotin in the presence or absence of
1 mM non-photoreactive ATP. A control without UV photolysis was set
up in parallel. The samples were resolved by SDS-PAGE and transferred
to PVDF membrane for western blot analysis. The bound 8-azido-ATP
was visualized by ExtrAvidin-HRP and anti-FLAG antibody was used to
detect the proteins.
doi:10.1371/journal.pone.0005315.g001
Figure 2. 8-azido-ATP binding to SVOP-FLAG is saturable and
displays a binding affinity of 83 mM. Purified SVOP-FLAG was
labeled with the indicated concentrations of 8-azido-ATP-biotin and
subjected to SDS-PAGE and western blot analysis. The net intensity of
the regions of interest was quantified using a Kodak Image Station 440.
A, Representative western blot result of SVOP-FLAG labeling as a
function of 8-azido-ATP concentration. B, Quantification of the western
data. The data were expressed as the intensity of 8-azido-ATP labeling
normalized to SVOP protein signals. The error bars represent SEM
(n=4).
doi:10.1371/journal.pone.0005315.g002
Figure 3. Nucleotide specificity of the 8-azido-ATP binding to
SVOP. SVOP-FLAG was labeled with 100 mM 8-azido-ATP in the
absence or presence of 1 mM indicated competitive nucleotides.
Samples were subjected to SDS-PAGE and western blot followed by
quantitative analysis. Panel A shows a representative western blot
result. Panel B shows the quantification of the western blot data. The
error bars represent SEM, n=5.
doi:10.1371/journal.pone.0005315.g003
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amine cleavage at this bond is predicted to generate an N-terminal
fragment of 31.7 KDa and a C-terminal fragment of 30.1 KDa.
As shown in Figure 5A, hydroxylamine cleavage of SVOP-FLAG
produced a fragment with an apparent molecular mass of 35 KDa
that was labeled by an antibody against an N-terminal sequence in
SVOP, and a fragment with an apparent molecular mass of
28.5 KDa that was recognized by an anti-FLAG antibody. The
photoaffinity-labeled fragment had the same apparent molecular
weight as the anti-FLAG (C-terminal) fragment. This indicates
that the nucleotide-binding site in SVOP falls within the carboxyl-
terminal half of the protein (residues 286–548).
We next assessed binding by recombinant proteins correspond-
ing to the amino and carboxy halves of SVOP. Recombinant
FLAG fusion proteins containing the amino (Met
1- Val
267)o r
carboxy half (Asp
266-Glu
548) of SVOP (denoted SVOP
1–267 and
SVOP
266–548, respectively) were assessed for binding to 8-azido-
ATP. As with hydroxylamine-cleaved SVOP, apparent molecular
sizes of the FLAG tagged SVOP
1–267 and SVOP
266–548 in SDS-
PAGE (35 and 30 kDa, respectively) differed from the calculated
molecular weights of 30.9 and 32.4 kDa, respectively. Our
observation that the amino portion of SVOP resolves as a larger
protein in SDS-PAGE may reflect incomplete denaturation in
SDS. Likewise, the apparent smaller size of carboxy end is
consistent with this portion of SVOP being very hydrophobic. As
shown in Figure 5B, the C-terminal peptide, SVOP
266–548,
bound 8-azido-ATP whereas N-terminal half protein (SVOP
1–267 )
showed only minimal binding, confirming that the primary
nucleotide binding site in SVOP is located on the carboxy
terminal portion of the protein. Given that the N-terminal
fragment produced by hydroxylamine cleavage did not show
labeling, the very low level labeling in the N-terminal half protein
is probably due to the nonspecific binding of 8-azido-ATP.
Trypsin digestion of photolabeled SVOP further defined the site
of 8-azido-ATP attachment to SVOP. As shown in Figure 5C,
trypsin digestion produced a series of small proteolytic fragments
that labeled with ExtrAvidin-HRP and anti-FLAG antibody but
not anti-SVOP antibody. The smallest fragment that labeled with
both anti-FLAG antibody and 8-azido-ATP was ,15 KDa, which
suggests that the binding site is contained within amino acids 411–
548 of SVOP. To further define the region, we generated a series
of C-terminal truncations and found that SVOP lacking the last 30
amino acids (SVOP
1–518) retained the nucleotide binding
capability (data not shown). Together these data indicate that
the nucleotide-binding site in SVOP is located between a.a. 411–
518. We note, however, that the tendency of the carboxy end of
SVOP to run smaller in SDS-PAGE suggests that the actual
binding site may include residues preceding a.a. 411.
The nucleotide binding sites in SV2 and another MF
transporter protein, Glut1, are in cytoplamic domains. To
determine if this is also true of SVOP, we mutated residues that
are – conserved in SVOP across species - in the loops between
membrane domains 8/9 and 10/11. SVOP-E450A, SVOP-
Y425A, SVOP-R457A and the double mutant, G398A/R399A,
which is analogous to residues required for nucleotide binding to
Glut 1 [30], were tested for binding to 8-azido ATP. As shown in
Figure 6, all mutant SVOP proteins demonstrated nucleotide
binding similar to wild-type SVOP, indicating that the binding site
does not depend on these conserved residues. Theses results also
demonstrate that the ATP binding site in Glut1 is not conserved in
SVOP.
Discussion
SV2 and SVOP are transporter-like components of synaptic
vesicles that share significant sequence similarity although they
constitute separate protein families. SV2 proteins contain features
not present in SVOP including the cytoplasmic amino terminus,
the cytoplasmic loop between the sixth and seventh transmem-
brane domains and a luminal glycosylated loop between the
seventh and eighth transmembrane domains. In the studies
reported here we report that both SVOP and SV2 are
nucleotide-binding proteins although both the binding site and
nucleotide preference differ between the two proteins. SVOP
appears to have a binding site located in a region spanning
transmembrane domains 9–12, whereas SV2 has two binding sites
in its large cytoplasmic domains preceding transmembrane
domains 1 and 7 [18]. And whereas SVOP demonstrates the
highest affinity for NAD (IC50,0.25 mM versus ,0.75 mM for
ATP), SV2 shows an equal affinity for both NAD and ATP
(,0.4 mM for both).
Nucleotide binding is also a feature of the human glucose
transporter (Glut1), another member of the MF transporter family
[31]. Nucleotides decrease Glut1 transport activity, thus generat-
ing an inverse relationship between transporter activity and
cellular energy levels. In Glut1, the nucleotide-binding site was
Figure 4. SVOP demonstrates highest affinity for NAD. SVOP-
FLAG was labeled with 100 mM 8-azido-ATP in the absence or presence
of ATP (0.25–1.5 mM) or NAD (0.25–1.5 mM). Data were expressed as
the percentage of 8-azido-ATP labeling according to control with no
ATP or NAD in the reaction. A and B were representative western blot
results of SVOP labeling in the presence of different concentration of
ATP (A) or NAD (B). C shows the quantification of the western blot
results. Error bars represent SEM, n=3. The half maximum inhibition
concentration of NAD and ATP on SVOP ATP binding is about 0.25 mM
and 0.75 mM, respectively.
doi:10.1371/journal.pone.0005315.g004
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domains 8–9. A comparison of the binding sites in SVOP, SV2
and Glut1 is depicted in Figure 7, which indicate the nucleotide
binding sites are different among them.
Our studies indicate that nucleotide binding is a shared feature
of multiple MF transporters, though this feature appears to have
arisen separately in each of the proteins. As more is learned about
the molecular actions of SV2 and SVOP, it will be important to
compare the effects of nucleotides on these actions to the effects of
nucleotides reported for Glut1. The fact that both SV2 and SVOP
demonstrate a high affinity for NAD suggests their action may be
influenced by the rate of synaptic glycolysis, a process that
consumes NAD, or by synaptic redox potential. It will be
especially interesting to determine whether the apparent conver-
gent evolution of nucleotide binding in MF transporters has
rendered them sensitive to the same cellular conditions.
Materials and Methods
Plasmids
cDNA encoding rat SVOP with the FLAG epitope
(DYKDDDK) fused to its C-terminus was subcloned into the
mammalian expression vectors pIRES2–EGFP (Clontech, Moun-
tain View, CA). Constructs encoding N-terminal and C-terminal
halves of SVOP protein were generated by PCR amplification of
rat SVOP cDNA and subcloned into FLAG-pIRES2–EGFP
vector. The QuikChange Site-Directed mutagenesis Kit (Strata-
gene) was used to generate mutant SVOP constructs. These
include single point mutations, E450A, Y452A, R457A, and a
double mutation G398A/R399A.
The primers used include: E450A f 59- TAC ACG CCT GCG
GTG TAT CCA ACG GCG ACG AGG-39, E450A r 59- TGG
ATA CAC CGC AGG CGT GTA AAC GTA GGC TGC TTG-
Figure 5. The nucleotide binding site in SVOP localizes to the C-terminal half of the protein. A. 8-azido-ATP photoaffinity labeled SVOP-
FLAG was cleaved by hydroxylamine and the samples were subjected to western blot analysis using anti-FLAG, anti-SVOP and ExtrAvidin-HRP.
Arrowhead indicated an N-terminal fragment which is recognized by anti-SVOP antibody but not labeled by 8-azido-ATP. The Arrows indicate a C-
terminal fragment which is labeled by 8-azido-ATP and anti-FLAG antibody. B. Only the C-terminal half of SVOP shows dominant nucleotide binding.
N- and C-terminal halves of SVOP-FLAG were expressed and purified from HEK293 cells. Photoaffinity labeling was performed as described under
Methods. C. Shown are the results of trypsin digestion of 8-azido-ATP labeled SVOP-FLAG. Labeled protein was digested at 37uC in the presence of
trypsin. At the time periods indicated, an aliquot was withdrawn and subjected to analysis as described under Methods. The arrowheads indicate the
smallest trypsinized 15 kDa fragment which is labeled by both 8-azido-ATP and anti-FLAG antibody. The proportion of total anti-FLAG and 8-azido-
ATP labeling (undigested protein) was similar for the 15 KDa fragment (,9% in both cases), consistent with it being labeled with the same efficiency
as the full-length protein. Therefore the nucleotide-binding site is contained within this 15 KDa fragment. The image of 8-azido-ATP labeling blot was
adjusted with contrast to show better results.
doi:10.1371/journal.pone.0005315.g005
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AGG GCG-39, Y452A r 59- CGC CGT TGG CGC CAC CTC
AGG CGT GTA AAC-39, R457A f 59- A ACG GCG ACG GCG
GCG CTG GGC CTG GGC ACC TG-39, R457A r 59- GCC
CAG CGC CGC CGT CGC CGT TGG ATA CAC CTC,
G398A/R399A f 59- GAC CGC CTG GCC GCC AAG AAG
ACC ATG GCT CTG-39, and G398A/R399A r 59- GGT CTT
CTT GGC GGC CAG GCG GTC GAT GAC CCA C-39. f and
r denote forward and reverse primers. Underlined letters indicate
mismatches. DNA sequencing was performed to confirm that no
undesired mutation was introduced by PCR.
Cell culture and transfection
HEK293 cell culture and transfection of the cells with the
Lipofectamine
TM 2000 reagent were performed as previously
described [18].
Production and Purification of SVOP-FLAG protein
SVOP-FLAG fusion protein and its mutants were generated as
described previously [18]. Final preparations were checked by
silver staining of SDS polyacrylamide gels and immunoblot with
anti-SVOP or anti-FLAG antibodies.
Photoaffinity labeling
Dried 8-azido-ATP[c] biotin (Affinity Labeling Technologies
Inc., Lexington, KY) was dissolved in the buffer (150 mM KAc,
10 mM HEPES-KOH (pH 7.4)). Appropriate amount of 8-azido-
ATP[c] biotin as indicated was mixed with SVOP preparation
and incubated on ice in the dark for 2 min. Generally, about 5 mg
of SVOP-FLAG protein preparation was used for each labeling
reaction and the final volume was 50 ml. After incubation, the
samples were irradiated with a hand-held UV lamp at 254 nm
(UVP, Inc., San Gabriel, CA) for 2 min. The UV-irradiated
samples were immediately diluted with SDS-PAGE sample buffer
containing b-mercaptoethanol, and subjected to SDS-PAGE and
western blot analysis as described below. For hydroxylamine
cleavage or proteolytic digestion experiments, the labeled samples
were added with DTT to a final concentration of 40 mM after
labeling. For the substrate specificity and competition studies,
competitive nucleotides were added into the affinity labeling
reactions.
SDS-PAGE and immunoblotting
SDS-PAGEwas performed using either precast 4%–15% gradient
gels (Bio Rad Laboratories, Hercules, CA) or 10% gels. Proteins were
electro-transferred onto polyvinylidene difluoride membranes
(PVDF) (Millipore, Billerica, MA) and subjected to western blot
analysis. The primary antibodies used include a monoclonal anti-
FLAG M2 antibody (Sigma, Saint Louis, MO) and a polyclonal
rabbit anti-SVOP antibody made against N-terminally derived
peptides of SVOP (LRQLPVVKFRRTGES). Membranes were
then incubated with the appropriate horseradish peroxidase (HRP)
conjugated secondary antibody, washed and immune complexes
were visualized using an enhanced chemiluminescence detection kit
(Pierce, Rockford, IL). The 8-azido-ATP[c] biotin labeled samples
were probed with ExtrAvidin-HRP (Sigma, Saint Louis, MO) and
visualized by chemiluminescence. The net intensity of the regions of
interest was quantified using a Kodak Image Station 440, and only
the nonsaturated images were used for quantification analysis. The
image of 8-azido-ATP labeling blot with trypsin digested SVOP-
FLAG (Figure 5C) was adjusted with contrast to show better results.
Hydroxylamine cleavage of photolabeled protein
5–10 mg of 8-azido-ATP[c] biotin labeled SVOP- FLAG
protein was mixed with equal volume of hydroxylamine cleavage
reaction buffer (3M hydroxylamine-HCl, 3M guanidine-HCl,
adjusted to pH 9.0 with NaOH) and incubated at 45uC for 4 h.
The cleavage reaction samples were then desalted by passing
through Zeba desalt spin columns (Pierce, Rockford, IL). Aliquots
of non-cleaved and cleaved samples were resolved by SDS-PAGE
and subjected to western blot analysis with anti-FLAG, anti-SVOP
and ExtrAvidin-HRP as described above.
Proteolytic digestion of photolabeled protein
8-azido-ATP[c] biotin labeled SVOP- FLAG protein was
digested at 37uC in the presence of sequencing grade trypsin
Figure 6. Mutants of SVOP show normal nucleotide binding.
Mutated SVOP constructs were generated by site-directed mutagenesis.
Photoaffinity labeling with 8-azido-ATP was performed with the
wildtype and the mutated proteins. All the mutants show similar
binding capability as the wild type.
doi:10.1371/journal.pone.0005315.g006
Figure 7. Comparison of the nucleotide binding sites in Glut1,
SV2A and SVOP. Comparison of the nucleotide binding sites in Glut1,
SV2A and SVOP suggests convergent evolution of nucleotide binding.
Predicted 12 transmembrane domains are depicted. Red lines represent
the nucleotide binding domains. The amino and carboxy termini of the
proteins are indicated with letter N and C.
doi:10.1371/journal.pone.0005315.g007
SVOP Binds Nucleotide
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Mannheim, Germany). At the time periods indicated, an aliquot
was withdrawn and the digestion terminated by adding phenyl-
methylsulfonyl fluoride (PMSF) to a final concentration of 1 mM.
The samples were subjected to SDS-PAGE and western blot
analysis.
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